<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172417</url>
  </required_header>
  <id_info>
    <org_study_id>205.222</org_study_id>
    <nct_id>NCT02172417</nct_id>
  </id_info>
  <brief_title>Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects</brief_title>
  <official_title>The Effect of Concomitant Cimetidine p.o. 400 mg t.i.d. and p.o. Ranitidine 300 mg Once Daily on Single Dose Pharmacokinetics of Tiotropium (14.4 µg) Given Intravenously Over 15 Minutes in Healthy Male and Female Subjects of 50-65 Years (Randomized, Open Label, Two Independent Two-fold Crossover)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the effect of an inhibition of the renal cationic drug transporter on
      single dose pharmacokinetics of intravenous tiotropium in subjects in an age close to typical
      Chronic Obstructive Pulmonary Disease (COPD) population
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <primary_completion_date type="Actual">November 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of plasma levels of tiotropium after dosing</measure>
    <time_frame>up to 8 hours after i.v. treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) 0-4h of the plasma levels of tiotropium after dosing</measure>
    <time_frame>0 - 4 hours after i.v. treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary excretion 0-4h after dosing (Ae0-4h)</measure>
    <time_frame>0 - 4 hours after i.v. treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance of tiotropium (CLR)</measure>
    <time_frame>pre-dose, 0-4 h, 4-8 h, 8-12 h, 12-24 , 24-28 h, 38-72 h and 72-96 h after i.v. treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC 0-8h of plasma levels of tiotropium after dosing</measure>
    <time_frame>0-8 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion 0-96h after dosing (Ae0-96h)</measure>
    <time_frame>0-96 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>up to 4 - 8 days after last i.v. treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Laboratory Tests</measure>
    <time_frame>Baseline, 4 - 8 days after last i.v. treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>up to 24 h after i.v. treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Blood Pressure and Pulse Rate</measure>
    <time_frame>up to 4 - 8 days after last i.v. treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in physical examination</measure>
    <time_frame>Baseline, 4 - 8 days after last i.v. treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cimetidine + Tiotropium followed by Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranitidine + Tiotropium followed by Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimetidine + Tiotropium</intervention_name>
    <arm_group_label>Cimetidine + Tiotropium followed by Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine + Tiotropium</intervention_name>
    <arm_group_label>Ranitidine + Tiotropium followed by Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <arm_group_label>Cimetidine + Tiotropium followed by Tiotropium</arm_group_label>
    <arm_group_label>Ranitidine + Tiotropium followed by Tiotropium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females

          -  Age range from 50 to 65 years

          -  Within 20% of their normal weight (Broca index)

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, puls rate and ECG)
             deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Diseases of the central nervous system (such as epilepsy) or with psychiatric
             disorders or neurological disorders

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of a drug with a long half-life (≥ 24 hours) within ten half-lives of the
             respective drug before enrolment in the study or during the study (exclusion: ovarian
             hormone substitution)

          -  Use of any drugs which might influence the results of the trial within four weeks
             prior to administration or during the trial, among these all non-selective β-blockers,
             cromolyn sodium, nedocromil sodium, oral β-adrenergics or long-acting β-adrenergics
             such as salmeterol and formoterol, and anticholinergic drugs including ATROVENT®
             (ipratropium) by oral inhalation or ATROVENT® Nasal Spray

          -  Participation in another study with an investigational drug within two months prior to
             administration or during the trial

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day)

          -  Inability to refrain from smoking on study days

          -  Alcohol abuse (&gt; 40 g/day)

          -  Drug abuse

          -  Blood donation (≥ 100 ml) within four weeks prior to administration or during the
             trial

          -  Excessive physical activities within 5 days prior to administration or during the
             trial

          -  Any laboratory value outside the reference range of clinical relevance

          -  Subjects with known hypersensitivity to anticholinergic drugs

          -  Subjects with known symptomatic prostatic hypertrophy or disturbed micturition

          -  Subjects with known narrow-angle glaucoma

        In addition for female subjects (if appropriate):

          -  Pregnancy

          -  Positive pregnancy test

          -  No adequate contraception e.g. oral contraceptives, sterilization, intra uterine
             pessary (IUP)

          -  Inability to maintain this adequate contraception during the whole study period

          -  Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

